Mechanism of Action: Magnetic Resonance Contrast Activity
✉ Email this page to a colleague
Drugs with Mechanism of Action: Magnetic Resonance Contrast Activity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-005 | Nov 24, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-001 | Nov 1, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-002 | Nov 1, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-003 | Nov 1, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-004 | Aug 4, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Guerbet | DOTAREM | gadoterate meglumine | SOLUTION;INTRAVENOUS | 204781-002 | Mar 20, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
